The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction

Yu Kataoka, Shunichi Miyazaki, Satoshi Yasuda, Noritoshi Nagaya, Teruo Noguchi, Naoaki Yamada, Isao Morii, Atsushi Kawamura, Kaori Doi, Kunio Miyatake, Hitonobu Tomoike, Kenji Kangawa

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

Adrenomedullin (AM) is a 52-amino-acid vasodilator peptide that was originally isolated from human pheochromocytoma. In the previous experimental study with rat ischemia/reperfusion model, AM reduced infarct size and inhibited myocyte apoptosis. AM also suppressed the production of oxygen-free radicals. The present study was designed to evaluate the feasibility of intravenous administration of AM in patients with acute myocardial infarction. We studied 10 patients with first acute myocardial infarction [male to female ratio: 9 to 1, age: 65 ± 9 (mean ± SD) years, peak creatine phosphokinase level: 4215 ± 1933 (SD) U/L], who were hospitalized within 12 hours of symptom onset. Proceeding reperfusion therapy, AM infusion was initiated and continued at concentration of 0.0125-0.025 μg·kg-1·min -1 for 12 hours. Follow-up coronary angiography and left ventriculography were performed at 3 months. Cardiac magnetic resonance was examined at 1 month and 3 months after AM therapy. During infusion of AM, hemodynamics kept stable except 2 patients. Wall motion index in the infarct area at 3 months was significantly improved compared with that at baseline, and infarct size evaluated by cardiac magnetic resonance was significantly decreased at 3 months. In conclusion, intravenous administration of AM, which possesses a variety of potential cardiovascular protective actions, can be adjunctive to percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)413-419
Number of pages7
JournalJournal of cardiovascular pharmacology
Volume56
Issue number4
DOIs
Publication statusPublished - 2010 Oct

Keywords

  • acute myocardial infarction
  • adrenomedullin
  • cardioprotective therapy
  • reperfusion injury

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction'. Together they form a unique fingerprint.

Cite this